Phase III Clinical Trial Definition & Meaning | Health Care Term | CSIMarket
CSI Market
Sign In | Register

Glossary

Phase III Clinical Trial

Health Care Term

A Phase III clinical trial is a randomized controlled study that is conducted on a large group of patients to evaluate the efficacy and safety of a new medical treatment or drug. This phase of clinical trials is usually the last step in the drug development process before the medication is submitted to regulatory agencies for approval.

During a Phase III trial, investigators compare the new treatment to the standard of care or a placebo to determine whether it has a significant therapeutic benefit. The study is typically conducted on several thousand patients across multiple centers around the world to ensure the reliability of the results.

Once the Phase III trial is completed, the data is analyzed to determine whether the new medication is safe and effective, and whether it meets the criteria for approval by regulatory agencies. Positive results can lead to the medication receiving regulatory approval and being released into the market for use by patients.

In the healthcare industry, Phase III clinical trials play a critical role in advancing medical knowledge, identifying new treatments and therapies, and improving patient outcomes. These trials provide the final opportunity for researchers to gather data on the effectiveness and safety of a new medication or treatment and determine whether it can be used to treat patients with confidence.

Overall, Phase III clinical trials are an essential component of the drug development process and play a critical role in advancing healthcare and improving patient outcomes.


More Glossary Terms Beginning with P
  • Paediatric Exclusivity
    means, in the US, a six-month period of exclusivity to market a drug which is awarded by the FDA in return for certain paediatric clinical studies using that drug. This six-month period runs from the date of relevant patent expiry.
    Health Care Term Letter: P
  • Paid Development Method
    An actuarial method to estimate ultimate losses for a given cohort of claims such as an accident year/product line component. If the paid-to-date losses are then subtracted from the estimated ultimate losses, the result is an indication of the unpaid losses. The basic premise of the method is that cumulative paid losses for a given cohort of claims will grow in a stable, predictable pattern from y
    Insurance Term Letter: P
  • Panelboards
    Oriented strand board, particleboard, medium density fibreboard and plywood. Operating Statistics
    Manufacturing Term Letter: P
  • Partial Remission PR
    A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
    Health Care Term Letter: P
  • Particleboard
    A panelboard produced by chemically bonding clean sawdust, small wood particles and recycled wood fibre under heat and pressure. Forestry & Wood Products Industry Operating Statistics
    Manufacturing Term Letter: P
  • Particulate Matter
    Total suspended particulate. A measure of the solid particles (wood, process dust and smoke) found in air emissions.
    Manufacturing Term Letter: P
  • Particulates
    Tiny particles of a substance.
    Manufacturing Term Letter: P
  • Passenger Load Factor
    Represents the total number of seats sold as a percentage of total seat capacity on all sectors flown. Airline Industry
    Transportation Term Letter: P
  • Passenger Mile Yield
    The amount of passenger revenue earned per revenue passenger mile during a reporting period Airline Industry
    Transportation Term Letter: P
  • Passenger revenue yield per Mile Average Yield per RPM
    Represents the average scheduled passenger fare revenue for each revenue passenger mile (RPM), or each mile a scheduled revenue passenger is flown. Airline Industry
    Transportation Term Letter: P
  • Passive Immunotherapy
    Immunologically active material transferred into the patient as a passive recipient. Monoclonal antibodies are considered Passive Immunotherapy since antibodies are generated outside the body and given to the patient
    Health Care Term Letter: P
  • Patent Term Extension
    means an extension of up to five years in the term of a US patent relating to a drug which compensates for delays in marketing resulting from the need to obtain FDA approval.
    Health Care Term Letter: P